Compare · CDNA vs CI
CDNA vs CI
Side-by-side comparison of CareDx Inc. (CDNA) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 28.1x CDNA ($2.63B).
- CDNA has been more active in the news (11 items in the past 4 weeks vs 8 for CI).
- CI has more recent analyst coverage (25 ratings vs 19 for CDNA).
- Company
- CareDx Inc.
- The Cigna Group
- Price
- -
- -
- Market cap
- $2.63B
- $73.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 11
- 8
- Recent ratings
- 19
- 25
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CDNA
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- SEC Form SCHEDULE 13G filed by CareDx Inc.
- Director Bickerstaff George sold $925,700 worth of shares (20,000 units at $46.28), decreasing direct ownership by 13% to 134,061 units (SEC Form 4)
- Director Cournoyer Christine sold $750,973 worth of shares (16,000 units at $46.94), decreasing direct ownership by 27% to 42,943 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam sold $124,349 worth of shares (2,688 units at $46.26) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,075 units (SEC Form 4)
- Director Goldberg Michael sold $2,103,497 worth of shares (44,700 units at $47.06), decreasing direct ownership by 42% to 61,738 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,872 shares, decreasing direct ownership by 3% to 108,763 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by CareDx Inc.
- SEC Form 144 filed by CareDx Inc.
Latest CI
- Cigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costs
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits